The recommended usual dose of vebreltinib is 2 capsules (50 mg per capsule) taken orally once daily, and the specific dosage must be adjusted strictly in accordance with a doctor’s instructions. As a prescription drug, its dosage regimen shall be tailored to the individual patient based on their condition, physical status and drug response; the dosage must not be increased, reduced or the medication discontinued without medical advice.
I. Dosage Instructions
Standard dose
2 capsules (100 mg) taken once daily is the usual dosage. It is recommended to take the medication at a fixed time to maintain a stable blood drug concentration.
Dosage adjustment
In the event of severe adverse reactions (e.g., abnormal liver function, interstitial lung disease, etc.), the doctor may reduce the dosage to 1 capsule (50 mg) or suspend the medication.
II. Precautions for Administration
Administration method
Swallow the capsules whole, either with meals or on an empty stomach. If a dose is missed, take the missed dose if more than 12 hours remain until the next scheduled dose; otherwise, skip the missed dose.
Contraindications and precautions
The drug is contraindicated in patients with hypersensitivity to any of its components. Caution is advised in patients with hepatic or renal insufficiency and underlying cardiopulmonary diseases, who require enhanced clinical monitoring during treatment.
III. Adverse Reaction Management
Common reactions
These include diarrhea, rash, fatigue and other symptoms, which can usually be relieved with symptomatic treatment.
Severe risks
Seek immediate medical attention if symptoms such as dyspnea, persistent fever or abnormal liver function indicators occur.
IV. Compliance with Medical Advice and Follow-up Visits
Regular rechecks
During the course of medication, blood tests and imaging examinations are required to evaluate treatment efficacy and drug safety, and the doctor will adjust the treatment regimen based on the results.
Drug interactions
Inform the doctor of all other medications currently being taken (e.g., anticoagulants, antiepileptics, etc.) to avoid the risks associated with combined drug use.
V. Medical Consultation Guidelines
vebreltinib is available only with a medical prescription, and patients must not decide on the use of the drug on their own. Genetic testing (e.g., MET exon14 skipping mutation, etc.) should be completed prior to treatment to confirm that the patient meets the indication criteria. If disease progression occurs or adverse reactions are intolerable during treatment, patients must communicate with their attending physician in a timely manner to adjust the treatment regimen.
